Despite significant advancements in malaria prevention tools, nearly half of the world's population remains at risk of malaria transmission. Experts continue to stress the importance of a diverse arsenal to achieve effective malaria prevention.
One such promising measure is monoclonal antibodies, three of which are in different clinical trial stages and are backed by key players including the United States National Institutes of Health and the Gates Foundation.
Trevor Mundel, president of global health at the Gates Foundation, described them as the newest product class for the prevention of malaria.
Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).
About the author
Paul Adepojupauladepoju
Paul Adepoju is a Nigeria-based Devex Contributing Reporter, academic, and author. He covers health and tech in Africa for leading local and international media outlets including CNN, Quartz, and The Guardian. He's also the founder of healthnews.africa. He is completing a doctorate in cell biology and genetics and holds several reporting awards in health and tech.
